CD8A and neoplasm: Macitentan inhibited the secretion of EV PD-L1 by targeting endothelin receptor A (ETA), thereby enhancing CD8+ T cell-mediated tumor killing and improving the efficacy of PD-L1 blockade in BC models (98).